摘要
[目的]探讨术前化疗在晚期卵巢黏液性和浆液性上皮癌治疗中的作用。[方法]回顾分析我院182例晚期卵巢黏液性和浆液性上皮癌病例。无术前化疗组(A组),先行手术切除,术后辅以铂类为主的联合化疗6～8个疗程;术前化疗组(B组),先行以铂类药物为主化疗1～3个疗程,然后行手术治疗,术后再辅以铂类为主的联合化疗6～8个疗程。术前化疗组在以下6项:Ⅳ期病例、低分化病例、合并腹水、胸水的病例、CA125中位值和锁骨上淋巴转移等不利因素高于无术前化疗组(P<0.05)。[结果]满意的手术切除率A组59.2%、B组85.7%(P<0.05);术后并发症A组25.9%、B组10.9%(P<0.05);术后中位无进展生存期A组14个月、B组12个月(P>0.05)。[结论]术前化疗可以减少术后并发症发生率、提高满意的手术切除率,而不影响中位无进展生存期。晚期不能手术切除的卵巢上皮癌进行术前化疗有积极意义。
To investigate effect of neoadjuvant chemotherapy on advanced mucous and serum epithe-lial ovarian cancer.The hospital records of182women with advanced mucous and serum epithelial ovari-an cancer were retrospectively reviewed.There were group A without neoadjuvant chemotherapy that patients were operated firstly,and group B with neoadjuvant chemotherapy that patients were firstly treated with one to three cy-cles of cisplatin-based chemotherapy,then were operated.All patients were treated with six to eight cycles of cis-platin-based chemotherapy after operation.There were six disadvantageous aspects higher in group B than that in group A,such as stageⅣcases,low differentiation cases,ascites and hydrothorax complications,median CA125and superclavicular lymph node metastasis.The rates of optimal tumor reduction were59.2%in group A and85.7%in group B(P<0.05).The rates of postoperation complication were25.9%in group A and10.9%in group B(P<0.05).The median progress-free durations were fourteen months in group A and twelve months in group B respec-tively(P>0.05).[Conclusion]Neoadjuvant chemotherapy can reduce postoperative complications,and improve rate of optimal tumor reduction.But it did not affect the median progress-free survival.Neoadjuvant chemotherapy is signifi-cant to advanced ovarian cancer patients who are unoperable initially.
出处
《肿瘤学杂志》
CAS
2003年第2期65-67,共3页
Journal of Chinese Oncology
